AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 61.37B | 60.44B | 58.74B | 58.13B | 56.50B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.37B | 60.44B | 58.74B | 58.13B | 56.50B |
| Cost of Revenue | 11.17B | 11.11B | 10.68B | 9.66B | 9.95B |
| Gross Profit | 50.20B | 49.33B | 48.06B | 48.47B | 46.55B |
| SG&A Expenses | 21.27B | 20.55B | 20.15B | 19.30B | 19.40B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -343.00M | -270.00M | -162.00M | -253.00M | -189.00M |
| Total Operating Expenses | 46.48B | 45.65B | 44.61B | 42.39B | 42.32B |
| Operating Income | 14.89B | 14.79B | 14.13B | 15.74B | 14.18B |
| Income Before Tax | 12.59B | 12.91B | 12.40B | 11.44B | 10.02B |
| Income Tax Expenses | 2.13B | 2.52B | 2.17B | 2.04B | 1.72B |
| Earnings from Continuing Operations | 10.45K | 10.39K | 10.23K | 9.40K | 8.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -7.00M | -4.00M | -8.00M | -5.00M | -7.00M |
| Net Income | 10.45B | 10.39B | 10.23B | 9.40B | 8.30B |
| EBIT | 14.89B | 14.79B | 14.13B | 15.74B | 14.18B |
| EBITDA | 20.16B | 19.86B | 19.11B | 20.25B | 18.96B |
| EPS Basic | 6.74 | 6.70 | 6.59 | 6.06 | 5.35 |
| Normalized Basic EPS | 5.46 | 5.42 | 5.17 | 5.81 | 5.21 |
| EPS Diluted | 6.68 | 6.64 | 6.54 | 6.02 | 5.31 |
| Normalized Diluted EPS | 5.42 | 5.38 | 5.13 | 5.77 | 5.17 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.25B | 6.24B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 2.18 | 3.20 | 3.20 | 3.13 | 3.13 |
| Payout Ratio | 46.90% | 47.24% | 48.59% | 52.89% | 59.51% |